Toggle menu

EMBOL1

Start date:
June 2019
End date:
July 2020
Co-ordinated by:
LUMIRADx
Main trial site:
Manchester Royal Infirmary

Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). It is the third most frequent cardiovascular disease with an overall annual incidence of
100–200 per 100 000 inhabitants. VTE may be lethal in the acute phase or lead to chronic disease and disability, but it is also often preventable. This study aims to assess the precision and accuracy of the LumiraDx point of Care (POC) D Dimer test when used in patients presenting with symptoms of VTE which can deliver a quantitative result in under 10 minutes from a finger stick blood sample. Current tests require venous blood samples or are laboratory tests that take 30-60+ minutes to return a result to the attending clinician.

Primary Objective: To determine the performance of the LumiraDx POC D Dimer assay when compared to the VIDAS D-Dimer Exclusion reference method in patients with suspected VTE.

Secondary objectives:

  1. Performance evaluation of the haematocrit measurement by the LumiraDx POC D Dimer test with Hemocue Hb 201 system.
  2. Clinical performance of the LumiraDx POC D Dimer assay when used as an aid in the exclusion of DVT and PE.

Sample: Patients presenting to the Emergency department with symptoms of deep vein thrombosis or pulmonary embolism.

Trial design: Prospective observational (cohort) Performance evaluation study

Target – 100 (TBC)

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Polly Black

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Sian Dalgleish

Senior Research Nurse

Emma Nugent

Research Administrator

Fraser Craig

Clinical Trial Assistant

More EMERGE Trials

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions

MAPP2

The Markers and Paracetamol Poisoning Study 2

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

Read more

Garfield-VTE

Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events